Disitamab vedotin (RC48) is an innovative anti-HER2 ADC drug consisting of hertuzumab attached to monomethyl auristatin E (MMAE) via a cleavable linker that is approved for HER2-positive breast cancer in China.67 Disitamab vedotin has certain advantages over T-DM1, with good tolerability and good efficacy, even in patients with HER2-low expression. The gene discussed is ERBB2; the disease is breast carcinoma.